{"entity":{"id":"mst-0312","kind":"drug","name":"MST-0312","aka":[],"tldr":"MST-0312 is an experimental bispecific agonist antibody from Mestag Therapeutics, in phase 1 trials for advanced solid tumours.","summary":"MST-0312 is a bispecific agonist antibody from Mestag Therapeutics. A FAP-targeted bispecific antibody that activates the lymphotoxin-beta receptor (LTBR) in the tumour, to induce tertiary lymphoid structures and high endothelial venules that help the immune system attack the tumour. Its furthest stage is phase 1, for advanced solid tumours (initially non-small cell lung cancer, melanoma, bladder cancer, colorectal cancer and triple-negative breast cancer). ClinicalTrials.gov registers it in one study linked below. STARLYS phase 1 NCT07610941 recruiting; first patient dosed per release of 19 May 2026. Whether it works in people has not been established unless a trial below reports it.","status":"phase-1","asOf":"2026-11-03","links":[{"label":"Mestag Therapeutics: svhealthinvestors.com","url":"https://svhealthinvestors.com/news/mestag-therapeutics-announces-the-first-patient-dosed-with-mst-0312-in-the-phase-i-starlys-trial"},{"label":"Mestag Therapeutics: clinicaltrials.gov","url":"https://clinicaltrials.gov/study/NCT07610941"},{"label":"ClinicalTrials.gov: trials of MST-0312","url":"https://clinicaltrials.gov/search?intr=MST-0312"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":["fap"],"drugs":[],"companies":["mestag-therapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":["nct07610941"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo gap audit, class 5 (company pipeline pages and ClinicalTrials.gov v2)","editedOn":"2026-11-03"},"code":"MST-0312","modality":"Bispecific agonist antibody","mechanism":"A FAP-targeted bispecific antibody that activates the lymphotoxin-beta receptor (LTBR) in the tumour, to induce tertiary lymphoid structures and high endothelial venules that help the immune system attack the tumour.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/mst-0312/","neighbours":{"target":[{"id":"fap","kind":"target","name":"FAP","route":"/targets/fap/"}],"company":[{"id":"mestag-therapeutics","kind":"company","name":"Mestag Therapeutics","route":"/companies/mestag-therapeutics/"}],"trial":[{"id":"nct07610941","kind":"trial","name":"Phase 1 Open Label Trial of MST-0312 Alone and in Combination in Subjects With Solid Malignancies","route":"/trials/nct07610941/"}]}}